Nanogen
This article was originally published in The Gray Sheet
Executive Summary
Raises $3.5 mil. in first round of venture capital financing to fund development of DNA-based diagnostic tests using "ultraminiaturized silicon chips inlaid with artificial DNA to detect specific gene sequences," the firm says in a March 15 release. Investors include Enterprise Partners, Kleiner Perkins Caufield & Byers and Nanogen Chairman and CEO Howard Birndorf, who have "committed to additional funding as the company reaches certain milestones," the firm says.